Congenica goes Dutch to help cancer patients worldwide
Cambridge digital health trailblazer Congenica is working with Dutch company myTomorrows to expedite access to precision oncology for cancer patients across the globe.
Congenica provides software and solutions for genomic data analysis and interpretation while myTomorrows is a global platform facilitating access to pre-approval treatments and clinical trials.
The partnership will open new opportunities for physicians to search for access to pre-approval anti-cancer treatments and active clinical trials, specifically for patients whose cancers cannot be treated with approved treatment options.
The programme is set to launch in the first quarter of 2024 and will enable physicians to refer patients via Congenica’s Precision Oncology solution to the myTomorrows platform where they can search for applicable trials and request enrolment.
Alistair Johnson, Chief Professional Services Officer, at Congenica said: “We are thrilled to collaborate with myTomorrows to accelerate precision oncology and provide rapid access to clinical trials for patients facing limited treatment options.
“By combining our cutting-edge genomic data analysis platform with myTomorrows' global reach and pre-approval treatment connections, we can empower physicians to offer patients routes into active clinical trials and pre-approval therapeutic solutions that would otherwise be difficult to access.”
Michel van Harten, CEO at myTomorrows said that by collaborating on this initiative, “we can expand the pool of eligible patients for precision oncology clinical trials and offer better access to individuals who may not have had access to these opportunities otherwise.”